ES2175152T3 - Fosfolipidos protectores de las radiaciones. - Google Patents

Fosfolipidos protectores de las radiaciones.

Info

Publication number
ES2175152T3
ES2175152T3 ES96940103T ES96940103T ES2175152T3 ES 2175152 T3 ES2175152 T3 ES 2175152T3 ES 96940103 T ES96940103 T ES 96940103T ES 96940103 T ES96940103 T ES 96940103T ES 2175152 T3 ES2175152 T3 ES 2175152T3
Authority
ES
Spain
Prior art keywords
phospholipids
derivatized
disclosed
ether
radiation protective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES96940103T
Other languages
English (en)
Inventor
Oren Tirosh
Ron Kohen
Joshua Katzhendler
Yechezkel Barenholz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Application granted granted Critical
Publication of ES2175152T3 publication Critical patent/ES2175152T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/335—Polymers modified by chemical after-treatment with organic compounds containing phosphorus
    • C08G65/3353—Polymers modified by chemical after-treatment with organic compounds containing phosphorus containing oxygen in addition to phosphorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/14—Liposomes; Vesicles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cosmetics (AREA)
  • Medicinal Preparation (AREA)
  • Luminescent Compositions (AREA)
  • Radiation-Therapy Devices (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)

Abstract

SE EXPONEN NUEVOS FOSFOLIPIDOS VINCULADOS AL ETER, OBTENIDOS COMO DERIVACION CON POLIETILENGLICOL EN EL GRUPO DE LA CABEZA POLAR. LAS DOBLES CAPAS DE LIPIDOS QUE CONTIENEN ESTOS FOSFOLIPIDOS MUESTRAN UNA ELEVADA ESTABILIDAD OSCILATIVA. SE EXPONE IGUALMENTE EL USO DE LIPIDOS VINCULADOS AL ETER Y DERIVADOS DEL PEG EN COMPOSICIONES COSMETICAS HIDRATANTES Y PARA PROTECCION CONTRA LAS RADIACIONES.
ES96940103T 1995-12-11 1996-12-10 Fosfolipidos protectores de las radiaciones. Expired - Lifetime ES2175152T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/570,440 US5817856A (en) 1995-12-11 1995-12-11 Radiation-protective phospholipid and method

Publications (1)

Publication Number Publication Date
ES2175152T3 true ES2175152T3 (es) 2002-11-16

Family

ID=24279658

Family Applications (1)

Application Number Title Priority Date Filing Date
ES96940103T Expired - Lifetime ES2175152T3 (es) 1995-12-11 1996-12-10 Fosfolipidos protectores de las radiaciones.

Country Status (8)

Country Link
US (2) US5817856A (es)
EP (1) EP0900075B1 (es)
AT (1) ATE215360T1 (es)
AU (1) AU705529B2 (es)
DE (1) DE69620473T2 (es)
ES (1) ES2175152T3 (es)
IL (1) IL124732A0 (es)
WO (1) WO1997021429A1 (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method
US6306433B1 (en) * 1997-08-12 2001-10-23 Pharmacia Ab Method of preparing pharmaceutical compositions
US20040247662A1 (en) * 1998-06-25 2004-12-09 Dow Steven W. Systemic immune activation method using nucleic acid-lipid complexes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
WO2001051010A1 (en) * 2000-01-11 2001-07-19 Clinical Results, Inc. Dermatological suspensions (micro-matrix)
EP1254143B1 (en) * 2000-02-10 2004-09-29 Liplasome Pharma A/S Lipid-based drug delivery systems
US20050129722A1 (en) * 2002-03-13 2005-06-16 Collagenex Pharmaceuticals, Inc. Water-based delivery systems
AU2003233396B2 (en) * 2002-03-13 2007-05-24 Thomas Skold Water-based delivery systems
ITMI20021033A1 (it) * 2002-05-15 2003-11-17 Acraf Composizione oftalmica acquosa comprendente un lipide mesomorfico liotropico
EP1519714B1 (en) 2002-06-28 2010-10-20 Protiva Biotherapeutics Inc. Method and apparatus for producing liposomes
US7939170B2 (en) * 2002-08-15 2011-05-10 The Rockefeller University Water soluble metal and semiconductor nanoparticle complexes
WO2004022003A2 (en) 2002-09-06 2004-03-18 University Of South Florida Materials and methods for treatment of allergic diseases
US20080214437A1 (en) * 2002-09-06 2008-09-04 Mohapatra Shyam S Methods and compositions for reducing activity of the atrial natriuretic peptide receptor and for treatment of diseases
US20040166083A1 (en) * 2003-02-26 2004-08-26 The Andrew Jergens Company Personal care water-in-oil emulsion products
US20060198882A1 (en) * 2003-03-21 2006-09-07 Yechezkel Barenholz Stable liposomes or micelles comprising a sphinolipid and a peg-lipopolymer
AU2004233873B2 (en) 2003-04-25 2010-11-18 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
CA2532228C (en) * 2003-07-16 2017-02-14 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
EP1664316B1 (en) * 2003-09-15 2012-08-29 Protiva Biotherapeutics Inc. Polyethyleneglycol-modified lipid compounds and uses thereof
AU2005227870A1 (en) * 2004-02-17 2005-10-13 University Of South Florida Materials and methods for treatment of inflammatory and cell proliferation disorders
US20050181035A1 (en) * 2004-02-17 2005-08-18 Dow Steven W. Systemic immune activation method using non CpG nucleic acids
CA2569664C (en) 2004-06-07 2013-07-16 Protiva Biotherapeutics, Inc. Lipid encapsulated interfering rna
US20060116270A1 (en) * 2004-07-16 2006-06-01 Mehdi Hatamian Centrifuge system
WO2006027787A1 (en) * 2004-09-09 2006-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposomal compositions of glucocorticoid and glucocorticoid derivatives
JP2008512444A (ja) * 2004-09-09 2008-04-24 イッスム・リサーチ・ディベロップメント・カンパニー・オブ・ザ・ヘブルー・ユニバーシティ・オブ・エルサレム 神経変性状態の治療のための、両親媒性弱塩基様テンパミンを含むリポソーム製剤
WO2006051549A2 (en) * 2004-11-15 2006-05-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combination therapy associating preferably a ceramide with a cytotoxic drug
EP1824872B1 (en) * 2004-12-14 2012-02-08 Alnylam Pharmaceuticals Inc. Rnai modulation of mll-af4 and uses thereof
WO2006086992A2 (en) * 2005-02-18 2006-08-24 Liplasome Pharma A/S Drug delivery systems containing phqspholipase a2 degradable lipid prodrug derivatives and the therapeutic uses thereof as. e.g. wound healing agents and peroxisome proliferator activated receptor ligands
EP1962796A2 (en) * 2005-12-08 2008-09-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Methods for affecting liposome composition by ultrasound irradiation
US20070218116A1 (en) * 2006-03-14 2007-09-20 Schwendener Reto A Compositions and methods for the treatment of tumors and tumor metastases
WO2007127487A2 (en) * 2006-04-28 2007-11-08 University Of South Florida Materials and methods for reducing inflammation by inhibition of the atrial natriuretic peptide receptor
WO2007127428A2 (en) * 2006-04-28 2007-11-08 University Of Florida Research Foundation, Inc. Double-stranded/self-complementary vectors with a truncated cba promoter and methods of gene delivery
CA2600220C (en) * 2006-09-07 2014-12-09 Canadian Blood Services Surface cross-linked lipidic particles, methods of production and uses therefor
CA2721333C (en) 2008-04-15 2020-12-01 Protiva Biotherapeutics, Inc. Novel lipid formulations for nucleic acid delivery
EP2440250A1 (en) 2009-06-11 2012-04-18 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Targeted liposomes comprising n-containing bisphosphonates and uses thereof
US8569256B2 (en) 2009-07-01 2013-10-29 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
US9018187B2 (en) 2009-07-01 2015-04-28 Protiva Biotherapeutics, Inc. Cationic lipids and methods for the delivery of therapeutic agents
WO2011000107A1 (en) 2009-07-01 2011-01-06 Protiva Biotherapeutics, Inc. Novel lipid formulations for delivery of therapeutic agents to solid tumors
EP2531175A2 (en) 2010-02-01 2012-12-12 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Liposomes comprising amphipathic drugs and method for their preparation
US9006417B2 (en) 2010-06-30 2015-04-14 Protiva Biotherapeutics, Inc. Non-liposomal systems for nucleic acid delivery
CA3065178C (en) 2010-12-13 2022-02-01 Quiapeg Pharmaceuticals Ab Functionalized polymers
US10184942B2 (en) 2011-03-17 2019-01-22 University Of South Florida Natriuretic peptide receptor as a biomarker for diagnosis and prognosis of cancer
RS61235B1 (sr) 2011-07-13 2021-01-29 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Lipozomi koji ko-inkapsuliraju bisfosfonat i amfipatički agens
AU2013276219B2 (en) 2012-06-12 2018-03-08 Quiapeg Pharmaceuticals Ab Conjugates of biologically active molecules to functionalized polymers
US10406088B2 (en) 2015-01-20 2019-09-10 TetraDerm Group LLC Versatile topical drug delivery vehicle and multifactorial tissue moisturizer that provides mucosal and skin barrier restoration
WO2016149516A1 (en) 2015-03-17 2016-09-22 Lipomedix Pharmaceuticals Ltd. Methods for the treatment of bladder cancer
CN105439827A (zh) * 2016-01-12 2016-03-30 江苏省计量科学研究院 一种1,2-O-双十六烷基-rac-甘油的合成方法
KR20190125310A (ko) 2017-03-10 2019-11-06 퀴아펙 파마슈티칼스 에이비 방출가능한 접합체
EP4295895A3 (en) 2017-05-11 2024-03-27 Tc1 Llc Thermal interconnect for implantable blood pump
CA3112473A1 (en) 2018-09-12 2020-03-19 Quiapeg Pharmaceuticals Ab Releasable glp-1 conjugates
FR3089814B1 (fr) * 2018-12-18 2021-04-02 Oreal Procede de traitement des fibres keratiniques comprenant l’application d’un agent de couplage et d’un phospholipide, composition et utilisation
WO2022115645A1 (en) 2020-11-25 2022-06-02 Akagera Medicines, Inc. Lipid nanoparticles for delivery of nucleic acids, and related methods of use
CN114796055B (zh) * 2022-05-19 2023-08-15 广东艾粒生物科技有限责任公司 富含脂质体纳米粒的美白敷料及其制备方法
CA3256897A1 (en) 2022-05-25 2023-11-30 Akagera Medicines, Inc. Lipid nanoparticles for the administration of nucleic acids and their methods of use

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2408387A2 (fr) * 1975-06-30 1979-06-08 Oreal Compositions a base de dispersions aqueuses de spherules lipidiques
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US5153000A (en) * 1988-11-22 1992-10-06 Kao Corporation Phosphate, liposome comprising the phosphate as membrane constituent, and cosmetic and liposome preparation comprising the liposome
US5013556A (en) * 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
DE69103487T2 (de) * 1990-07-11 1995-02-16 Quest Int Parfümierte strukturierte Emulsionen in Körperpflegemitteln.
FR2676924B1 (fr) * 1991-05-31 1995-02-03 Saint Laurent Parfums Yves Microemulsion contenant un concentre parfumant et produit correspondant.
JPH07316040A (ja) * 1994-03-29 1995-12-05 Res Dev Corp Of Japan 再構成リポソームと物質導入方法
US5817856A (en) * 1995-12-11 1998-10-06 Yissum Research Development Company Of The Hebrew University Of Jerusalem Radiation-protective phospholipid and method

Also Published As

Publication number Publication date
EP0900075A1 (en) 1999-03-10
ATE215360T1 (de) 2002-04-15
AU705529B2 (en) 1999-05-27
US6165501A (en) 2000-12-26
DE69620473T2 (de) 2002-11-14
IL124732A0 (en) 1999-01-26
DE69620473D1 (de) 2002-05-08
WO1997021429A1 (en) 1997-06-19
EP0900075B1 (en) 2002-04-03
AU7707596A (en) 1997-07-03
US5817856A (en) 1998-10-06

Similar Documents

Publication Publication Date Title
ES2175152T3 (es) Fosfolipidos protectores de las radiaciones.
AU653999B2 (en) Compositions having a physiological cooling effect, and active compounds suitable for these compositions
BR9000673A (pt) Utilizacao em cosmetica de diorganopolissiloxanos com funcao benzotriazol,de um polimero estatistico ou em blocos e titulo de agente filtrante de radiacao uv,composicao cosmetica e processo de protecao da pele e dos cabelos e de protecao de uma composicao cosmetica
ITMI950493A0 (it) Frazioni polifenoliche di te' loro uso e formulazioni che le contengono
ES2139574T3 (es) Nuevos gases propulsores y su uso en preparaciones medicas.
MX9100199A (es) Composiciones antioxidantes naturales
DE69505962D1 (de) Mittel zur künstlichen bräunung mit verbesserter stabilität
ES2134777T3 (es) Nuevos compuestos de sulfonilo.
PL336000A1 (en) Cosmetic compositions containing a cationic polymer of low molecular weight and a silicone as well as their application
DE69428456D1 (de) Silikon-modifizierte phospholipid-zusammensetzungen
DE69406766D1 (de) Polyoxymetalate-Gruppen enthaltende Organosiloxan-Zusammensetzungen
ES2135169T3 (es) Cable resistente a las arborescencias.
ES2057004T3 (es) N-alcoxialquilamidas de hidroxiacidos y composiciones a base de las mismas para el tratamiento de la piel.
DK0487973T3 (da) Topisk lotion indeholdende niclosamid
EP0694605A3 (fr) Diesters cycliques et leur utilisation à titre d'ingrédients parfumants
ES2118386T3 (es) Procedimiento para la inactivacion de virus que no estan provistos de envolventes lipidicas.
ES2073878T3 (es) Utilizacion de la lactoferrina para la proteccion de la queratina de los cabellos contra las agresiones atmosfericas, en particular la luz, y procedimiento de proteccion de los cabellos utilizando ese compuesto.
ES2160308T3 (es) Nuevos derivados amino-metil-heterociclicos, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen.
FI925930A0 (fi) En kosmetisk eller dermatologisk blandning innehaollande en diolester
DK0801571T3 (da) Opløselige 2'-chlor-2'-deoxyadenosion-formuleringer
ES2054279T3 (es) Utilizacion en cosmetica de diorganopolisiloxanos con funcion dibenzoilmetano y nuevas composiciones cosmeticas que contienen estos compuestos, destinadas a la proteccion de la piel y los cabellos.
DK0420408T3 (da) Tandbehandlingspræparater
ATE262886T1 (de) Hautschutzzubereitung
NO20001352D0 (no) Hårkondisjoneringsblanding omfattende esterolje med høy molekylvekt
DE69733844D1 (de) SnF2 GEL MIT VERBESSERTER FORMFESTIGKEIT UND STABILITÄT

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 900075

Country of ref document: ES